Microdosing Mushrooms: A Natural Remedy For Depression?

Microdosing psilocybin, the active ingredient in magic mushrooms, has been an emerging topic of interest in the mental health community. Anecdotal reports and studies suggest that microdosing psychedelics can improve cognitive function, enhance mood, and reduce symptoms of anxiety and depression. However, it is important to note that the research on the effectiveness and safety of psilocybin is still ongoing, and it may not be suitable for everyone. Some studies have shown that psilocybin can lead to insomnia, increased anxiety, and poor mood in certain individuals. Nonetheless, the potential benefits of microdosing psilocybin for depression are promising, and further research is being conducted to explore its efficacy and safety.

Microdosing mushrooms may improve mood and mental health

Microdosing psilocybin, the psychoactive ingredient in magic mushrooms, has been found to improve mood and mental health. Observational studies suggest that microdosing psilocybin can improve cognitive function and alleviate symptoms of depression and anxiety. A large study found that individuals who microdose psilocybin showed improved mood and a greater decline in anxiety, depression, and stress over a one-month period than those who did not microdose. These improvements were also observed in individuals with mental health concerns.

Psilocybin works differently from conventional antidepressants, making the brain more flexible and fluid, and less entrenched in the negative thinking patterns associated with depression. It fosters greater connections between different regions of the brain in depressed people, freeing them up from long-held patterns of rumination and excessive self-focus. The improvement in depressive symptoms correlates with changes to the brain, and these changes lasted until the end of the study, three weeks after the second psilocybin dose.

A study by Bright et al. analyzed 339 participants in different groups: yoga practitioners, microdosers, yoga practitioners and microdosers combined, and a control group. Results indicated that the combined microdosing and yoga group had the highest psychological well-being and absorption scores, with lower depression and anxiety scores compared to individual practices. Another study by Cameron et al. surveyed 2,347 participants to assess microdosing prevalence and demographics and explore reasons for discontinuation. Results showed that 59% of respondents were familiar with microdosing, and 17% had practiced it. Participants reported improved mood, reduced anxiety, and enhanced memory, attention, and sociability.

However, it is important to note that the use of regular doses of psilocybin can also produce unpleasant and terrifying experiences, also referred to as "bad trips." Microdosing, on the other hand, involves consuming small amounts of psychedelic substances that do not produce hallucinogenic effects. Most microdosers use about 10% of the regular dose of psilocybin, equivalent to about 100-300 milligrams of dried mushrooms, between 2-5 times a week. While microdosing mushrooms may show promise in improving mood and mental health, more rigorously designed clinical trials are needed to confirm these findings.

Microdosing psilocybin can have adverse effects

One of the main concerns with microdosing psilocybin is the potential for adverse effects. While microdosing typically involves taking a fraction of a regular dose of psilocybin, it can still lead to negative side effects such as insomnia, increased anxiety and depression, poor mood, low energy, physical discomfort, poor focus, and impaired social skills. These side effects can be particularly dangerous for individuals with psychotic conditions, such as schizophrenia or severe bipolar disorder, for whom psilocybin is not considered safe.

In addition, the potency of mushrooms can vary greatly, and it is difficult to know the exact dosage when consuming psilocybin outside of clinical trials. This lack of regulation increases the risk of accidental overdose or adverse reactions. Furthermore, there is a risk of adulteration with dangerous substances, such as fentanyl, which can be difficult to detect.

Another concern is the potential for physiological tolerance to develop, leading to diminishing returns over time. While microdosing is intended to avoid the hallucinogenic effects associated with regular doses of psilocybin, there is still a risk of unintentional "bad trips" or unpleasant experiences, even at lower doses.

While microdosing psilocybin has shown some promising results in observational studies, the lack of rigorous clinical trials and potential for adverse effects underscores the need for further research to fully understand the benefits and risks associated with this practice.

Psilocybin treatment for major depression

Psilocybin, the active ingredient in magic mushrooms, has shown promise in treating major depressive disorder in adults. While the nonmedical use of psilocybin typically refers to consuming mushrooms containing the substance, synthetic production is complicated and expensive.

Psilocybin can be consumed by eating fresh or dried mushrooms, or by making them into a tea. Microdosing refers to consuming very small amounts of psilocybin (about one-tenth or one-twentieth of a typical nonclinical dose) with the belief that it will improve mental health symptoms. Microdosers often combine their psilocybin with other substances, such as lion's mane mushrooms and niacin, which may enhance its effects.

Research has shown that psilocybin therapy "flattens" the brain's landscape, reducing connections within brain areas that are tightly connected in depression, and increasing connections to other regions. This allows for healthier flexibility and diversity in thought patterns, and makes it easier for new thoughts, insights, and perspectives to emerge. One hypothesis is that psilocybin briefly disrupts overactive connections in the brain, giving them a chance to reform in new ways in the following days and weeks. This is supported by brain scans, which show that the improvement in depressive symptoms correlates with changes to the brain.

A study by Johns Hopkins Medicine found that psilocybin-assisted therapy, given with supportive psychotherapy, may relieve symptoms of major depressive disorder for at least a year for some patients. The researchers reported that treatment produced large decreases in depression, with a 75% response and 58% remission at 12 months. However, it is important to note that the results were observed in a research setting with structured support from trained clinicians and therapists, and people should not attempt to try it on their own. Further research is needed to explore the possibility that the efficacy of psilocybin treatment may be substantially longer than 12 months.

While microdosing psilocybin has been associated with improvements in mood and mental health, it is not clear if it is safe or effective. Some sources suggest that microdosing can lead to insomnia, increased anxiety and depression, poor mood, low energy, physical discomfort, poor focus and cognitive functioning, and impaired social skills.

Microdosing and yoga for psychological well-being

Microdosing and yoga have both been suggested to have positive effects on psychological well-being. Microdosing involves taking a low dose of a psychedelic substance, such as psilocybin mushrooms, with the intention of improving mental health and cognitive functioning. On the other hand, yoga is a mind-body practice that combines physical postures, breathing techniques, and meditation to promote mental and physical health.

Microdosing for Psychological Well-being

Microdosing has gained popularity as a potential treatment for various mental health conditions, including depression. Psilocybin, the active compound in "magic mushrooms", has been the focus of research for its therapeutic potential. Some studies have found that psilocybin treatment can lead to significant and long-lasting reductions in depression severity. For example, a study by Johns Hopkins University reported that psilocybin treatment produced large decreases in depression scores, with effects lasting up to 12 months. However, it is important to note that psilocybin is not without risks and can lead to adverse effects such as increased anxiety, insomnia, and poor cognitive functioning.

Yoga for Psychological Well-being

Yoga has been recognized for its mental health benefits, including reduced anxiety and depression. It helps calm and center the mind through breathing practices and meditation. Studies have shown that regular yoga practice can lead to improved cognitive skills, enhanced mental clarity, and better sleep quality. Additionally, yoga has been found to increase hormones that contribute to happiness and mental well-being. The adaptability of yoga makes it accessible to people of all ages and fitness levels, promoting self-improvement and self-awareness.

Combining Microdosing and Yoga

Some research has explored the combination of microdosing and yoga practices. A study by Samantha Bettinson compared groups practicing yoga, microdosing, both yoga and microdosing, and a control group. The results indicated that the group practicing both yoga and microdosing had lower depression and anxiety scores than the microdosing-only group. Additionally, this combined group scored higher on psychological well-being and absorption compared to the control group. While these findings suggest that the combination of microdosing and yoga may be beneficial, more research is needed to understand their interaction and potential synergistic effects.

In conclusion, both microdosing and yoga have been associated with improved psychological well-being. While microdosing may provide relief from depression and anxiety, it also carries potential risks and side effects. Yoga, on the other hand, is a safe and effective complementary approach that can be used in conjunction with other treatments. Combining microdosing with contemplative practices like yoga may help mitigate unwanted effects and enhance overall psychological well-being. However, further research is warranted to fully understand the complex interactions between these two practices.

Microdosing as an alternative to ECT

Microdosing psilocybin, the active ingredient in magic mushrooms, has shown promise in treating depression. While research is still ongoing, initial findings suggest that microdosing can improve cognitive function and alleviate symptoms of depression and anxiety.

Psilocybin works differently from conventional antidepressants, making the brain more flexible and fluid. It reduces connections within brain areas that are tightly connected in depression, including the default mode, salience, and executive networks, and increases connections to other regions of the brain. This frees people with depression from long-held patterns of rumination and excessive self-focus, allowing new thoughts, insights, and perspectives to emerge.

A study by Johns Hopkins University School of Medicine found that psilocybin treatment produced large decreases in depression, with severity remaining low one, three, six, and twelve months after treatment. The researchers emphasized that psilocybin has the potential to relieve the symptoms of depression with one or two treatments, compared to standard antidepressants that must be taken for extended periods.

Another study by the University of British Columbia, the largest longitudinal study on microdosing psilocybin to date, showed that individuals who microdosed psilocybin had improved mood and a greater decline in anxiety, depression, and stress over a one-month period than those who did not microdose.

Despite the promising results, it is important to note that the safety and efficacy of microdosing are not yet fully understood. Some negative side effects of psilocybin include insomnia, increased anxiety and depression, poor mood, low energy, physical discomfort, poor focus and cognitive functioning, and impaired social skills. Additionally, psilocybin is not safe for people with psychotic conditions.

As an alternative to microdosing, electroconvulsive therapy (ECT) is often considered the "gold standard" in the treatment of treatment-resistant depression (TRD). However, ECT has its own challenges, including stigma, high costs, and invasiveness. In contrast, microdosing psilocybin is less expensive, more accessible, and has a better side effect profile than ECT. While more research is needed, microdosing psilocybin shows potential as a viable alternative to ECT in the treatment of TRD.

Frequently asked questions